Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60

Authors:

Abstract
BACKGROUND.: The clinical and pathologic features of 46 patients 40 to 60 years old with Ewing sarcoma family tumor (ESFT) diagnosed at the authors' institute between 1972 and 2000 were reviewed.METHODS.: Ten patients with metastatic tumors at presentation went elsewhere for treatment; 35 of 36 remaining cases with localized disease were treated at the authors' institution according to different chemotherapy protocols activated in successive years. In patients with nonmetastatic tumors local treatment was surgery in 9 patients, radiotherapy in 16, and surgery followed by radiotherapy in 10.RESULTS.: At follow‐up times ranging from 6 and 34 years (mean, 17.8 years), 15 patients (42.9%) remained continuously disease‐free, 19 experienced recurrence, and 1 died of chemotherapy‐related toxicity. The 5‐ and 10‐year event‐free survivals were 42.9% and 35.2%, respectively, and the 5‐ and 10‐year overall survivals were 46.1% and 42.8%, respectively. Comparing this group of patients with 586 cases of younger patients seen in the same period at Rizzoli, the only difference between the 2 groups was a significantly higher rate of tumors located in the soft tissues with a larger volume in the older group. The results achieved were comparable in the 2 groups, although the older group had a lower chemotherapy dose‐intensity and a higher rate of WHO grade 4 hematologic toxicity.CONCLUSIONS.: For patients with localized disease treated with adjuvant and neoadjuvant chemotherapy the results were essentially comparable in the 2 groups. It is concluded that patients 40 years or older with ESFT should be treated in the same way as younger patients and included in treatment trials for these tumors. Cancer 2007. © 2007 American Cancer Society.

This publication has 20 references indexed in Scilit: